Pulsed-field ablation

High-Voltage Focal Pulsed Field Ablation Achieves Transmurality and 98% Reduction in Scar-Related Ventricular Tachycardia

By MedXY 01/18/2026

The first-in-human VCAS trial demonstrates that high-voltage focal pulsed field ablation (PFA) safely delivers transmural lesions in thick ventricular scar tissue, significantly reducing ventricular tachycardia burden by 98% in high-risk patients with ischemic and non-ischemic substrates.

Cardiology news

Nanosecond Pulsed Field Ablation Matches Radiofrequency Efficacy While Slashing Procedure Time: Insights From the InsightPFA Trial

By MedXY 12/26/2025

The InsightPFA trial confirms that a novel nanosecond pulsed field ablation (nsPFA) system is noninferior to radiofrequency ablation for paroxysmal atrial fibrillation, significantly reducing procedure and left atrial dwell times while maintaining a comparable safety profile.

Cardiology news

Pulsed Field Ablation Demonstrates Exceptional Safety in Real-World Practice: Insights from the 40,000-Patient MANIFEST-US Study

By MedXY 12/25/2025

The MANIFEST-US study of over 40,000 patients confirms that pulsed field ablation (PFA) for atrial fibrillation maintains a high safety profile in real-world U.S. clinical practice, with a major complication rate of just 0.63% and a complete absence of esophageal fistulas or pulmonary vein stenosis.

Cardiology news Specialties

ADVANTAGE AF Phase 2: Evaluating Pulsed Field Ablation for Persistent Atrial Fibrillation Using Continuous ECG Monitoring

By MedXY 08/17/2025

The ADVANTAGE AF Phase 2 study demonstrates pulsed field ablation's safety and efficacy for persistent atrial fibrillation, introducing continuous cardiac monitoring to better assess arrhythmia burden and outcomes over one year.

Cardiology news Specialties

Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial

By MedXY 08/17/2025

This randomized trial compares sedation regimens for pulsed-field ablation in atrial fibrillation, finding remimazolam-ketamine deep analgosedation superior to propofol-opioid approaches in reducing hypoxemia and hypotension.